Sector
PharmaceuticalsOpen
₹480Prev. Close
₹485.65Turnover(Lac.)
₹322.27Day's High
₹492.2Day's Low
₹471.5552 Week's High
₹521.6552 Week's Low
₹325Book Value
₹140.51Face Value
₹1Mkt Cap (₹ Cr.)
7,936.18P/E
25.71EPS
18.87Divi. Yield
017 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
30 Aug 2023
12:00 AM
AGM
Announcement Date: 30 Aug, 2023
30 Aug 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 16.59 | 16.88 | 16.88 | 17.1 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,964.15 | 1,931.8 | 1,705.28 | 1,524.72 |
Net Worth | 1,980.74 | 1,948.68 | 1,722.16 | 1,541.82 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 1,325.44 | 1,331.09 | 1,062.19 | 1,008.91 |
yoy growth (%) | -0.42 | 25.31 | 5.28 | 2.23 |
Raw materials | -412.05 | -424.53 | -349.97 | -336.73 |
As % of sales | 31.08 | 31.89 | 32.94 | 33.37 |
Employee costs | -294.31 | -276.18 | -215.46 | -189.93 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 380.45 | 325.45 | 233.9 | 255.66 |
Depreciation | -37.62 | -37.36 | -35.03 | -34.52 |
Tax paid | -85.96 | -78.68 | -65.59 | -62.71 |
Working capital | 22.62 | 78.25 | 14.4 | 16.61 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.42 | 25.31 | 5.28 | 2.23 |
Op profit growth | 14.36 | 29.42 | -9.44 | 6.6 |
EBIT growth | 16.71 | 39.76 | -8.46 | 10.17 |
Net profit growth | 19.33 | 46.61 | -10.02 | 10.75 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,942.94 | 1,783.75 | 1,527.92 | 1,333.2 | 1,344.19 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,942.94 | 1,783.75 | 1,527.92 | 1,333.2 | 1,344.19 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 101.63 | 49.86 | 76.09 | 97.03 | 68.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Mohan A Chandavarkar
Director
Ashok A Chandavarkar
Joint Managing Director
Nandan M Chandavarkar
Executive Director & CEO
Ameya A Chandavarkar
Chairman Emeritus
Ramdas A Chandavarkar
Company Sec. & Compli. Officer
Varsharani Katre
Director
Nomita R Chandavarkar
Independent Director
Swati S Mayekar
Chairman & Independent Directo
Uday Kumar Gurkar
Independent Director
MELARKODE GANESAN PARAMESWARAN
Independent Director
Usha Athreya Chandrasekhar
Independent Director
Mahesh Bijlani
Addtnl Independent Director
Vijay Maniar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by FDC Ltd
Summary
FDC Limited is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). FDCs formulation department designs and develops products for various global markets and the highly regulated markets of US and Europe. The company has built a visible presence in the Regulated and Emerging markets. Promoted as a partnership firm in 1936 by the late Anand Chandravarkar to import pharmaceutical dosage forms, specialised infant foods and surgical goods Fairdeal Corporation (P) Ltd, as the company was known, was converted into a private limited company in September 23rd, 1940. It set up a formulation unit at Jogeshwari, Bombay in 1949.FDC has 2 wholly owned subsidiaries namely FDC Inc., USA and FDC International Ltd, UK and 1 Joint Venture business, namely Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. at South Africa as on 31 March 2019.FDC manufactures Electral, oral rehydration salt (ORS), being a leader in this segment. FDC manufactures bulk drugs, formulations and food products. The plant at Roha manufactures pharma dosage forms, food products and bulk drugs for the anti-rheumatic, anti-asthmatic, opthalmic and ENT segments. The company part financed its technical upgradation/modernisation/backward integration/expansion plans from the proceeds of its initial public issue in Jan.96. The company set up a modern manufacturing plant at Goa for manufacture
Read More
What is the FDC Ltd share price today?
The FDC Ltd shares price on N/A is Rs.₹491.65 today.
What is the Market Cap of FDC Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of FDC Ltd is ₹8004.56 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of FDC Ltd?
The PE and PB ratios of FDC Ltd is 25.71 and 3.77 as of 22 Jul ‘24
What is the 52 Week High and Low of FDC Ltd?
The 52-week high/low is the highest and lowest price at which a FDC Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of FDC Ltd is ₹325 and ₹523.9 as of 22 Jul ‘24
What is the CAGR of FDC Ltd?
FDC Ltd's CAGR for 5 Years at 24.92%, 3 Years at 9.05%, 1 Year at 48.08%, 6 Month at 9.48%, 3 Month at 8.12% and 1 Month at 5.33%.
What is the shareholding pattern of FDC Ltd?
The shareholding pattern of FDC Ltd is as follows:
Promoters - 69.66 %
Institutions - 9.24 %
Public - 21.10 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
